An organotypic model is helping researchers better understand disease processes in ulcerative colitis and colorectal cancer.
A $2.6 million grant from the National Cancer Institute will aid work to understand how colorectal cancer develops and spreads.
CAFs present in the rectal tumor microenvironment, when treated with radiation, increase the secretion of factors that contribute to tumor growth and cell migration. What this finding means for future treatment.
Bringing together expert scientists and clinicians to improve metastatic colon cancer’s bleak prognosis is the aim of Cleveland Clinic’s new Research Center of Excellence in Colon Cancer Metastasis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In a commentary about the discovery of CDX2, a new prognostic biomarker for stage II and stage III colon cancer, colorectal surgeon and researcher Emina Huang, MD, says the finding could help determine which patients might benefit from adjuvant chemotherapy. It might also suggest future therapeutic targets.
From intervening in colorectal-related cancer to utilizing a gold mine of outcomes data, discover how the latest bench research at Cleveland Clinic may one day improve outcomes for colorectal cancer patients.